{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:18:37Z","timestamp":1771474717550,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":72,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.nefroe.2021.11.007","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:27:50Z","timestamp":1640190470000},"page":"539-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin"],"prefix":"10.1016","volume":"41","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyasu","family":"Fukusumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsumi","family":"Kayaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2021.11.007_bib0155","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0160","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2188\/jea.10.403","article-title":"Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers","volume":"10","author":"Tomita","year":"2000","journal-title":"J Epidemiol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0165","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0170","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2215\/CJN.04271007","article-title":"High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes","volume":"3","author":"Rosolowsky","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0175","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1523-1755.2005.00459.x","article-title":"Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan","volume":"68","author":"Tseng","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0180","doi-asserted-by":"crossref","first-page":"F481","DOI":"10.1152\/ajprenal.00092.2009","article-title":"Effect of lowering uric acid on renal disease in the type 2 diabetic db\/db mice","volume":"297","author":"Kosugi","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0185","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10157-014-0935-8","article-title":"Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout","volume":"18","author":"Hosoya","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0190","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","article-title":"Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)","volume":"22","author":"Wada","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0195","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/nep.13177","article-title":"Renoprotective effects of topiroxostat for hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): a prospective, randomized, multicentre clinical trial","volume":"23","author":"Mizukoshi","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0200","first-page":"5","article-title":"Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats","author":"Kawamorita","year":"2017","journal-title":"Physiol Rep"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0205","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejphar.2016.03.055","article-title":"Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db\/db mice","volume":"780","author":"Nakamura","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0210","first-page":"24","article-title":"Topiroxostat showed renoprotection via various mechanisms including suppression of xanthine oxidoreductase-induced-oxidative stress and inflammation in db\/db mice","volume":"1","author":"Nakamura","year":"2016","journal-title":"J Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0215","doi-asserted-by":"crossref","first-page":"F1366","DOI":"10.1152\/ajprenal.00517.2015","article-title":"Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury","volume":"310","author":"Kamijo-Ikemori","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0220","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-020-01854-3","article-title":"New insight into podocyte slit diaphragm, a therapeutic target of proteinuria","volume":"24","author":"Kawachi","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0225","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1097-2765(00)80057-X","article-title":"Positionally cloned gene for a novel glomerular protein\u2013nephrin\u2014is mutated in congenital nephrotic syndrome","volume":"1","author":"Kestil\u00e4","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0230","first-page":"486","article-title":"Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes","volume":"67","author":"Floege","year":"1992","journal-title":"Lab Invest"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0235","first-page":"450","article-title":"Therapeutic targets in the podocyte: findings in anti-slit diaphragm antibody-induced nephropathy","volume":"22","author":"Kawachi","year":"2009","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0240","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.ASN.0000037401.02391.76","article-title":"Cloning of rat homologue of podocin: expression in proteinuric states and in developing glomeruli","volume":"14","author":"Kawachi","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0245","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1681\/ASN.V133630","article-title":"A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression","volume":"13","author":"Saleem","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0250","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1046\/j.1523-1755.2000.00044.x","article-title":"Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states","volume":"57","author":"Kawachi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0255","doi-asserted-by":"crossref","first-page":"F1376","DOI":"10.1152\/ajprenal.00075.2008","article-title":"Dissociation of NEPH1 from nephrin is involved in development of a rat model of focal segmental glomerulosclerosis","volume":"295","author":"Otaki","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0260","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1172\/JCI7728","article-title":"Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin","volume":"104","author":"Topham","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0265","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00047.x","article-title":"Podocyte injuries exacerbate mesangial proliferative glomerulonephritis","volume":"60","author":"Morioka","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0270","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1681\/ASN.V9112013","article-title":"Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes","volume":"9","author":"Matsui","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0275","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1681\/ASN.2017090993","article-title":"Nephrin-binding ephrin-B1 at the slit diaphragm controls podocyte function through the jNK pathway","volume":"29","author":"Fukusumi","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0280","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ajpath.2019.10.015","article-title":"Partitioning-Defective-6-Ephrin-B1 interaction is regulated by nephrin-mediated signal and is crucial in maintaining slit diaphragm of podocyte","volume":"190","author":"Takamura","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0285","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1083\/jcb.139.1.193","article-title":"Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes","volume":"139","author":"Mundel","year":"1997","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0290","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1097\/01.ASN.0000076078.50889.43","article-title":"Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: aminopeptidase P and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels","volume":"14","author":"Matsui","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0295","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00441-015-2178-8","article-title":"Alteration in the podoplanin-ezrin-cytoskeleton linkage is an important initiation event of the podocyte injury in puromycin aminonucleoside nephropathy, a mimic of minimal change nephrotic syndrome","volume":"362","author":"Suzuki","year":"2015","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.nefroe.2021.11.007_bib0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2353\/ajpath.2008.080063","article-title":"Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model","volume":"173","author":"Koop","year":"2015","journal-title":"Am J Pathol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251421001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251421001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:47:03Z","timestamp":1761853623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251421001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2013251421001139"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.11.007","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2020.10.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}